About AesRx
AesRx is a company based in Newton (United States) founded in 2009 was acquired by Baxter in July 2014. AesRx has raised $1.96 million across 4 funding rounds from investors including Baxter and HHS. AesRx operates in a competitive market with competitors including Editas Medicine, GBT, LogicBio, Kedrion and Modus Therapeutics, among others.
- Headquarter Newton, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Aesrx, Llc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of AesRx
AesRx has successfully raised a total of $1.96M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $400 thousand completed in September 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AesRx
AesRx has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Baxter and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Biosciences, medication delivery, and renal products are developed and marketed.
|
Locked | Locked | Locked |
Investor details for AesRx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AesRx
Investment portfolio details for AesRx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AesRx
Detailed financials for AesRx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aesrx Comparisons
Peer comparison for AesRx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AesRx
AesRx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Editas Medicine, GBT, LogicBio, Kedrion and Modus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed using CRISPR technology.
|
|
| Locked | Locked | Locked |
Small molecules are developed for sickle cell disease treatment.
|
|
| Locked | Locked | Locked |
Viral vectors are developed for genetic and infectious disease treatments.
|
|
| Locked | Locked | Locked |
Plasma-derived therapies are developed for hemophilia and immune deficiencies.
|
|
| Locked | Locked | Locked |
Polysaccharide-based drug for Sickle Cell Disease treatment is developed.
|
|
| Locked | Locked | Locked |
Therapies for sickle cell disease and diabetic nephropathy are developed.
|
Detailed competitors of AesRx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aesrx
Complete news archive for AesRx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AesRx
AesRx was founded in 2009 and raised its 1st funding round 2 years after it was founded.
AesRx is headquartered in Newton, United States. It is registered at Newton, Massachusetts, United States.
AesRx is a funded company, having raised a total of $1.96M across 4 funding rounds to date.
AesRx was founded in 2009 in Newton, United States, as a clinical-stage biotechnology company. Focus was placed on developing therapies for sickle cell disease, with operations centered on small molecule compounds. The lead candidate, Aes-103 (5-hydroxymethylfurfural), was advanced to phase 2 trials to enhance hemoglobin oxygen affinity and reduce red blood cell sickling, addressing outcomes like vaso-occlusive crises and anemia. Acquisition by Baxter occurred in July 2014.
AesRx's top competitors include GBT, Editas Medicine and Kedrion.